An interventional study of Catheter-based renal artery electrical stimulation (as a feasibility assessment for renal denervation) in Atrial Fibrillation (Paroxysmal), Hypertension and Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Pavel Antiperovitch. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Pavel Antiperovitch · Not applicable, Interventional, and Treatment
High blood pressure is a major risk factor for atrial fibrillation (AF), an irregular heart rhythm, and heart failure with preserved ejection fraction (HFpEF), a condition in which the heart becomes stiff and cannot relax properly. Both conditions can significantly affect quality of life and frequently occur together. In individuals with high blood pressure, increased activity of the nerves surrounding the kidneys can further elevate blood pressure and contribute to strain on the heart.
Renal denervation (RDN) is a procedure designed to lower blood pressure by reducing the activity of these nerves using a thin catheter and controlled energy. RDN has been shown to lower blood pressure safely in many patients; however, the potential benefits in individuals with concurrent AF and HFpEF remain uncertain.
This pilot study will be conducted in two phases. Phase 1 will assess the safety and feasibility of accessing the renal arteries and evaluating blood pressure responses to brief electrical stimulation of the renal nerves.
3,958 studies on the registry are indexed under Atrial Fibrillation; 933 are open to participants now.
This study's planned enrollment of 10 is below the median of 145 across 2,437 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →This is the only study on the registry with Pavel Antiperovitch as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
There is no control group, placebo group, or comparator arm. All enrolled participants undergo the same study procedure during their scheduled VT/PVC ablation.
Procedure: Catheter-based renal artery electrical stimulation (as a feasibility assessment for renal denervation)
During a scheduled EP study ± VT/PVC ablation: Renal arteries are selectively visualized with angiography. The ablation catheter is advanced into each renal artery. Electrical stimulation is delivered: 10 V, 0.4 ms pulse width, 100 ms cycle length, 30 seconds per renal artery Blood pressure response is measured through arterial monitoring. A positive response is defined as ≥10 mmHg increase in systolic blood pressure.
Technical Success Rate of Renal Artery Cannulationn
The proportion of patients in whom successful renal artery cannulation is achieved, as documented by the procedural operator. Technical success will be determined by successful catheter placement within the renal artery, allowing the planned procedure to proceed. Results will be reported as the number of successful cannulations divided by the total number of attempted cannulations, expressed as a percentage.
Time frame: At the time of the procedure
Successful Delivery of Electrical Stimulation
The proportion of patients in whom electrical stimulation can be successfully delivered to the renal artery using the planned stimulation protocol.
Time frame: At the time of the procedure
Change in Invasive Arterial Blood Pressure During Renal Artery Stimulation
The proportion of patients demonstrating a hypertensive response during renal artery stimulation, defined as an increase in systolic blood pressure of at least 10 mmHg compared with baseline, as measured using an arterial line
Time frame: At the time of procedure
Started Aug 2026 (actual). Primary completion is estimated for Aug 2029, 36 months after the start.
Of 789 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 36 months is close to that.
Counting every sponsor, half of 1,031 studies reached it within 34 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.